GKOS has been the topic of a number of other research reports. Cantor Fitzgerald reaffirmed a buy rating and set a $41.00 price target on shares of Glaukos Corp. in a research note on Sunday, September 25th. Zacks Investment Research downgraded shares of Glaukos Corp. from a buy rating to a hold rating in a research note on Monday, August 15th. Roth Capital increased their price target on shares of Glaukos Corp. from $36.50 to $41.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. Finally, Piper Jaffray Cos. increased their price target on shares of Glaukos Corp. to $42.00 in a research note on Tuesday, August 2nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $37.80.
Glaukos Corp. (NYSE:GKOS) opened at 37.74 on Tuesday. Glaukos Corp. has a 1-year low of $14.25 and a 1-year high of $39.82. The firm’s market cap is $1.25 billion. The firm has a 50 day moving average of $33.69 and a 200 day moving average of $27.10.
Glaukos Corp. (NYSE:GKOS) last announced its quarterly earnings results on Monday, August 1st. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. Glaukos Corp. had a negative net margin of 1.23% and a negative return on equity of 1.14%. The company had revenue of $28.60 million for the quarter, compared to the consensus estimate of $24.45 million. During the same quarter in the prior year, the firm earned ($1.30) earnings per share. The company’s revenue for the quarter was up 60.7% compared to the same quarter last year. On average, equities research analysts expect that Glaukos Corp. will post $0.10 EPS for the current year.
In other news, Director Orbimed Advisors Llc sold 425,000 shares of the stock in a transaction on Wednesday, August 3rd. The shares were sold at an average price of $30.59, for a total value of $13,000,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jonathan Silverstein sold 292,938 shares of the stock in a transaction on Friday, August 12th. The stock was sold at an average price of $33.69, for a total transaction of $9,869,081.22. The disclosure for this sale can be found here. 36.80% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Iguana Healthcare Management LLC purchased a new stake in Glaukos Corp. during the first quarter worth $2,042,000. Wellington Management Group LLP purchased a new stake in Glaukos Corp. during the first quarter worth $10,352,000. Fuller & Thaler Asset Management Inc. purchased a new stake in Glaukos Corp. during the second quarter worth $8,482,000. Blair William & Co. IL purchased a new stake in Glaukos Corp. during the second quarter worth $882,000. Finally, State Street Corp raised its stake in Glaukos Corp. by 6.7% in the first quarter. State Street Corp now owns 93,937 shares of the company’s stock worth $1,584,000 after buying an additional 5,862 shares during the last quarter. 71.91% of the stock is owned by institutional investors.
About Glaukos Corp.
Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.
Receive News & Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related companies with MarketBeat.com's FREE daily email newsletter.